Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 508

1.

HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients.

Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo MM, Peine S, Göke B, Lohse AW, Lütgehetmann M, Pischke S.

J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30169-7. doi: 10.1016/j.jhep.2018.02.031. [Epub ahead of print]

PMID:
29551705
2.

Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.

Op den Winkel M, Nagel D, Op den Winkel P, Trojan J, Paprottka PM, Steib CJ, Schmidt L, Göller M, Stieber P, Göhring P, Herbst A, Rentsch M, De Toni EN, Göke B, Gerbes AL, Kolligs FT.

Eur J Gastroenterol Hepatol. 2018 Jan;30(1):44-53. doi: 10.1097/MEG.0000000000001005.

PMID:
29076939
3.

γ-Catenin acts as a tumor suppressor through context-dependent mechanisms in colorectal cancer.

Nagel JM, Lahm H, Ofner A, Göke B, Kolligs FT.

Int J Colorectal Dis. 2017 Sep;32(9):1243-1251. doi: 10.1007/s00384-017-2846-0. Epub 2017 Jul 6.

PMID:
28681073
5.

Screening for Colorectal Cancer Is Associated With Lower Disease Stage: A Population-Based Study.

Kubisch CH, Crispin A, Mansmann U, Göke B, Kolligs FT.

Clin Gastroenterol Hepatol. 2016 Nov;14(11):1612-1618.e3. doi: 10.1016/j.cgh.2016.04.008. Epub 2016 Apr 13.

PMID:
27085763
6.

Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis.

De Toni EN, Ziesch A, Rizzani A, Török HP, Hocke S, Lü S, Wang SC, Hucl T, Göke B, Bruns C, Gallmeier E.

Oncotarget. 2016 Feb 23;7(8):9477-90. doi: 10.18632/oncotarget.7053.

7.

A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.

Hocke S, Guo Y, Job A, Orth M, Ziesch A, Lauber K, De Toni EN, Gress TM, Herbst A, Göke B, Gallmeier E.

Oncotarget. 2016 Feb 9;7(6):7080-95. doi: 10.18632/oncotarget.6857.

8.

Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.

Nölting S, Maurer J, Spöttl G, Aristizabal Prada ET, Reuther C, Young K, Korbonits M, Göke B, Grossman A, Auernhammer CJ.

PLoS One. 2015 Dec 4;10(12):e0143830. doi: 10.1371/journal.pone.0143830. eCollection 2015.

9.

Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice.

Schmohl KA, Müller AM, Schwenk N, Knoop K, Rijntjes E, Köhrle J, Heuer H, Bartenstein P, Göke B, Nelson PJ, Spitzweg C.

Eur Thyroid J. 2015 Sep;4(Suppl 1):74-80. doi: 10.1159/000381019. Epub 2015 May 23.

10.

Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.

Reuther C, Heinzle V, Spampatti M, Vlotides G, de Toni E, Spöttl G, Maurer J, Nölting S, Göke B, Auernhammer CJ.

Neuroendocrinology. 2016;103(3-4):383-401. doi: 10.1159/000439431. Epub 2015 Aug 25.

PMID:
26338447
11.

Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3.

Schmohl KA, Müller AM, Wechselberger A, Rühland S, Salb N, Schwenk N, Heuer H, Carlsen J, Göke B, Nelson PJ, Spitzweg C.

Endocr Relat Cancer. 2015 Dec;22(6):941-52. doi: 10.1530/ERC-15-0245. Epub 2015 Aug 25.

12.

Solid Organ Transplantation in Patients with Inflammatory Bowel Diseases (IBD): Analysis of Transplantation Outcome and IBD Activity in a Large Single Center Cohort.

Schnitzler F, Friedrich M, Stallhofer J, Schönermarck U, Fischereder M, Habicht A, Karbalai N, Wolf C, Angelberger M, Olszak T, Beigel F, Tillack C, Göke B, Zachoval R, Denk G, Guba M, Rust C, Grüner N, Brand S.

PLoS One. 2015 Aug 19;10(8):e0135807. doi: 10.1371/journal.pone.0135807. eCollection 2015.

13.

[Fecal microbiota transfer (FMT) in a patient with refractory irritable bowel syndrome].

Zoller V, Laguna AL, Prazeres Da Costa O, Buch T, Göke B, Storr M.

Dtsch Med Wochenschr. 2015 Aug;140(16):1232-6. doi: 10.1055/s-0041-103798. Epub 2015 Aug 11. German.

PMID:
26261935
14.

Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.

Lu S, Török HP, Gallmeier E, Kolligs FT, Rizzani A, Arena S, Göke B, Gerbes AL, De Toni EN.

Oncotarget. 2015 Sep 8;6(26):22167-78.

15.

The NOD2 Single Nucleotide Polymorphism rs72796353 (IVS4+10 A>C) Is a Predictor for Perianal Fistulas in Patients with Crohn's Disease in the Absence of Other NOD2 Mutations.

Schnitzler F, Friedrich M, Wolf C, Stallhofer J, Angelberger M, Diegelmann J, Olszak T, Tillack C, Beigel F, Göke B, Glas J, Lohse P, Brand S.

PLoS One. 2015 Jul 6;10(7):e0116044. doi: 10.1371/journal.pone.0116044. eCollection 2015.

16.

Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition.

Streckel E, Braun-Reichhart C, Herbach N, Dahlhoff M, Kessler B, Blutke A, Bähr A, Übel N, Eddicks M, Ritzmann M, Krebs S, Göke B, Blum H, Wanke R, Wolf E, Renner S.

J Transl Med. 2015 Feb 25;13:73. doi: 10.1186/s12967-015-0431-2.

17.

Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene.

Knoop K, Schwenk N, Schmohl K, Müller A, Zach C, Cyran C, Carlsen J, Böning G, Bartenstein P, Göke B, Wagner E, Nelson PJ, Spitzweg C.

J Nucl Med. 2015 Apr;56(4):600-6. doi: 10.2967/jnumed.114.146662. Epub 2015 Mar 5.

18.

[Advanced radioiodine-refractory differentiated thyroid cancer].

Spitzweg C, Auernhammer CJ, Geisler J, Böck S, Heinemann V, Bartenstein P, Göke B.

Dtsch Med Wochenschr. 2015 Feb;140(3):168-71. doi: 10.1055/s-0041-100196. Epub 2015 Feb 6. Review. German. No abstract available.

PMID:
25658401
19.

Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).

Schmidt L, op den Winkel M, Fischer K, Straub G, Rauch B, Paprottka PM, Göke B, Kolligs FT.

Digestion. 2014;90(4):219-28. doi: 10.1159/000367686. Epub 2014 Dec 9.

PMID:
25502689
20.

Anticancer effects of metformin on neuroendocrine tumor cells in vitro.

Vlotides G, Tanyeri A, Spampatti M, Zitzmann K, Chourdakis M, Spttl C, Maurer J, Nölting S, Göke B, Auernhammer CJ.

Hormones (Athens). 2014 Oct-Dec;13(4):498-508. doi: 10.14310/horm.2002.1517. Epub 2014 Nov 5.

21.

The NOD2 p.Leu1007fsX1008 mutation (rs2066847) is a stronger predictor of the clinical course of Crohn's disease than the FOXO3A intron variant rs12212067.

Schnitzler F, Friedrich M, Wolf C, Angelberger M, Diegelmann J, Olszak T, Beigel F, Tillack C, Stallhofer J, Göke B, Glas J, Lohse P, Brand S.

PLoS One. 2014 Nov 3;9(11):e108503. doi: 10.1371/journal.pone.0108503. eCollection 2014.

22.

Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.

Guo Y, Ziesch A, Hocke S, Kampmann E, Ochs S, De Toni EN, Göke B, Gallmeier E.

J Cell Mol Med. 2015 Feb;19(2):340-50. doi: 10.1111/jcmm.12444. Epub 2014 Oct 21.

23.

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?

de Heer J, Göke B.

Expert Opin Drug Saf. 2014 Nov;13(11):1469-81. doi: 10.1517/14740338.2014.955013. Epub 2014 Oct 1. Review.

PMID:
25270593
24.

Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.

Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B, Auernhammer CJ.

World J Gastroenterol. 2014 Aug 7;20(29):10038-49. doi: 10.3748/wjg.v20.i29.10038.

25.

DRO1 inactivation drives colorectal carcinogenesis in ApcMin/+ mice.

Grill JI, Neumann J, Herbst A, Hiltwein F, Ofner A, Marschall MK, Wolf E, Kirchner T, Göke B, Schneider MR, Kolligs FT.

Mol Cancer Res. 2014 Nov;12(11):1655-62. doi: 10.1158/1541-7786.MCR-14-0205-T. Epub 2014 Jul 22.

26.

Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study.

Beigel F, Teich N, Howaldt S, Lammert F, Maul J, Breiteneicher S, Rust C, Göke B, Brand S, Ochsenkühn T.

J Crohns Colitis. 2014 Nov;8(11):1471-9. doi: 10.1016/j.crohns.2014.05.009. Epub 2014 Jun 19.

PMID:
24953836
27.

Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.

Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, Brand S.

PLoS One. 2014 Jun 16;9(6):e99293. doi: 10.1371/journal.pone.0099293. eCollection 2014.

28.

Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.

Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):735-44. doi: 10.1002/pds.3621. Epub 2014 Apr 30.

PMID:
24788825
29.

Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice.

Nölting S, Giubellino A, Tayem Y, Young K, Lauseker M, Bullova P, Schovanek J, Anver M, Fliedner S, Korbonits M, Göke B, Vlotides G, Grossman A, Pacak K.

Endocrinology. 2014 Jul;155(7):2377-90. doi: 10.1210/en.2014-1027. Epub 2014 Apr 24.

30.

Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.

Beigel F, Friedrich M, Probst C, Sotlar K, Göke B, Diegelmann J, Brand S.

PLoS One. 2014 Apr 7;9(4):e93498. doi: 10.1371/journal.pone.0093498. eCollection 2014.

31.

Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹In-labelled exendin.

Brom M, Woliner-van der Weg W, Joosten L, Frielink C, Bouckenooghe T, Rijken P, Andralojc K, Göke BJ, de Jong M, Eizirik DL, Béhé M, Lahoutte T, Oyen WJ, Tack CJ, Janssen M, Boerman OC, Gotthardt M.

Diabetologia. 2014 May;57(5):950-9. doi: 10.1007/s00125-014-3166-3. Epub 2014 Feb 1.

PMID:
24488022
32.

Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling.

Herbst A, Jurinovic V, Krebs S, Thieme SE, Blum H, Göke B, Kolligs FT.

BMC Genomics. 2014 Jan 28;15:74. doi: 10.1186/1471-2164-15-74.

33.

GLP-1--a candidate humoral mediator for glucose control after Roux-en-Y gastric bypass.

Schirra J, Göke B.

Diabetes. 2014 Feb;63(2):387-9. doi: 10.2337/db13-1660. No abstract available.

34.

Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.

Aulinger BA, Bedorf A, Kutscherauer G, de Heer J, Holst JJ, Göke B, Schirra J.

Diabetes. 2014 Mar;63(3):1079-92. doi: 10.2337/db13-1455. Epub 2013 Dec 2.

35.

Intestinal DMBT1 expression is modulated by Crohn's disease-associated IL23R variants and by a DMBT1 variant which influences binding of the transcription factors CREB1 and ATF-2.

Diegelmann J, Czamara D, Le Bras E, Zimmermann E, Olszak T, Bedynek A, Göke B, Franke A, Glas J, Brand S.

PLoS One. 2013 Nov 5;8(11):e77773. doi: 10.1371/journal.pone.0077773. eCollection 2013.

36.

EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene.

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C.

Mol Ther Nucleic Acids. 2013 Nov 5;2:e131. doi: 10.1038/mtna.2013.58.

37.

Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.

Zitzmann K, Ailer G, Vlotides G, Spoettl G, Maurer J, Göke B, Beuschlein F, Auernhammer CJ.

Int J Oncol. 2013 Dec;43(6):1824-32. doi: 10.3892/ijo.2013.2130. Epub 2013 Oct 4.

38.

Role of cysteinyl-leukotrienes for portal pressure regulation and liver damage in cholestatic rat livers.

op den Winkel M, Gmelin L, Schewe J, Leistner N, Bilzer M, Göke B, Gerbes AL, Steib CJ.

Lab Invest. 2013 Dec;93(12):1288-94. doi: 10.1038/labinvest.2013.115. Epub 2013 Sep 23.

39.

[Diseases in gastroenterology].

Göke A, Göke B.

Internist (Berl). 2013 Oct;54(10):1185-96. doi: 10.1007/s00108-013-3290-z. Review. German. Erratum in: Internist (Berl). 2013 Nov;54(11):1322.

PMID:
24026789
40.

Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension.

Steib CJ, Gmelin L, Pfeiler S, Schewe J, Brand S, Göke B, Gerbes AL.

Life Sci. 2013 Oct 11;93(16):543-51. doi: 10.1016/j.lfs.2013.08.018. Epub 2013 Sep 3.

PMID:
24007798
41.

Photodynamic therapy for cholangiocarcinoma using low dose mTHPC (Foscan(®)).

Kniebühler G, Pongratz T, Betz CS, Göke B, Sroka R, Stepp H, Schirra J.

Photodiagnosis Photodyn Ther. 2013 Sep;10(3):220-8. doi: 10.1016/j.pdpdt.2012.12.005. Epub 2013 Jan 23.

PMID:
23993847
42.

Selectively N-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and Aβ40.

Yan LM, Velkova A, Tatarek-Nossol M, Rammes G, Sibaev A, Andreetto E, Kracklauer M, Bakou M, Malideli E, Göke B, Schirra J, Storr M, Kapurniotu A.

Angew Chem Int Ed Engl. 2013 Sep 23;52(39):10378-83. doi: 10.1002/anie.201302840. Epub 2013 Aug 19. No abstract available.

PMID:
23956012
43.

Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C.

J Nucl Med. 2013 Aug;54(8):1450-7. doi: 10.2967/jnumed.112.115493. Epub 2013 Jul 10.

44.

The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells.

Zitzmann K, Andersen S, Vlotides G, Spöttl G, Zhang S, Datta R, Culler M, Göke B, Auernhammer CJ.

Neuroendocrinology. 2013;98(2):128-36. doi: 10.1159/000353784. Epub 2013 Jul 31.

PMID:
23797089
45.

Effect of sleeve gastrectomy on postprandial lipoprotein metabolism in morbidly obese patients.

Waldmann E, Hüttl TP, Göke B, Lang R, Parhofer KG.

Lipids Health Dis. 2013 Jun 1;12:82. doi: 10.1186/1476-511X-12-82.

47.

A direct comparison of the prevalence of advanced adenoma and cancer between surveillance and screening colonoscopies.

Crispin A, Mansmann U, Munte A, Op den Winkel M, Göke B, Kolligs FT.

Digestion. 2013;87(3):170-5. doi: 10.1159/000348653. Epub 2013 Apr 27.

PMID:
23635429
48.

A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.

Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, Li Y, Zimmer A, Göke B, Sharkey KA, Storr M.

Neuropharmacology. 2013 Aug;71:255-63. doi: 10.1016/j.neuropharm.2013.03.029. Epub 2013 Apr 18.

49.

Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.

Gallmeier E, Bader DC, Kriegl L, Berezowska S, Seeliger H, Göke B, Kirchner T, Bruns C, De Toni EN.

PLoS One. 2013;8(2):e56760. doi: 10.1371/journal.pone.0056760. Epub 2013 Feb 27.

50.

Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults.

Graser A, Melzer A, Lindner E, Nagel D, Herrmann K, Stieber P, Schirra J, Mansmann U, Reiser MF, Göke B, Kolligs FT.

Gastroenterology. 2013 Apr;144(4):743-750.e2. doi: 10.1053/j.gastro.2012.12.041. Epub 2013 Feb 13.

PMID:
23415805

Supplemental Content

Support Center